Breaking News, Collaborations & Alliances

NCCN Receives Boehringer Grant to Study Volasertib

Will evaluate data and define the studies to further characterize safety and efficacy

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) has been awarded a $2 million grant from Boehringer Ingelheim to develop a program to scientifically evaluate and define the safety and clinical effectiveness of the investigational compound volasertib in the treatment of hematologic malignancies.   NCCN will initially evaluate existing data then define the data and type of studies necessary to further characterize the safety and clinical effectiveness of volasertib...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters